Clinical Trial

Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The primary objective of this study is to assess the efficacy, safety, and tolerability of BPN14770 in participants aged 9 to 45 years with JS.
Protocol Amendment History 3 changes
critical Primary endpoint(s) modified 2026-06-10
notable Primary completion moved earlier: 2030-01-31 -> 2027-12-31 2026-06-10
minor Completion moved earlier: 2030-01-31 -> 2027-12-31 2026-06-10
Trial Details
NCT Number NCT06717438
Lead Sponsor Shionogi
Conditions Jordan's Syndrome, PPP2R5D Neurodevelopmental Disorder
Enrollment 30 participants
Start Date 2025-05-13
Primary Completion 2027-12-31 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-09